About
Freenome develops a blood-based, multiomics screening platform designed for early cancer detection, utilizing both genomic and proteomic biomarkers. Their core technology employs machine learning algorithms to analyze complex patterns in blood samples, aiming to detect cancer signals prior to symptom onset and improve screening accessibility. Currently focused on colorectal cancer with their CRC-DETECT test, Freenome is conducting clinical trials to validate performance and expand their platform to detect multiple cancer types, with a goal of increasing survival rates through earlier diagnosis.
Focus Areas
Technology Focus
healthcare ai ml infrastructure
Quick Stats
Total Raised $854M
Founded 2014
Status private
Type scaleup
Explore More
Similar Companies
Viz.ai
San Francisco, United States
57%
1 shared category
2 shared AI types
Same country
Healthcare AI
Monai
Santa Clara, United States
57%
1 shared category
2 shared AI types
Same country
Healthcare AI
Lunit
Seoul, South Korea
52%
2 shared categories
1 shared AI type
Healthcare AICancer Detection
Tempus AI
Chicago, United States
48%
1 shared category
1 shared AI type
Same country
Healthcare AI